Advertisement

Tesaro's ovarian cancer drug gets EU agency backing

Tesaro's ovarian cancer drug gets EU agency backing
From Reuters - September 15, 2017

(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Tesaro Incs key drug, niraparib, for the treatment of recurrent ovarian cancer.

The recommendation comes months after the drugs approval and launch in the United States, where it is sold at a list price of $9,833 for a one-month supply and is marketed as Zejula.

The list price of a drug is not necessarily what patients actually pay. Their out-of-pocket cost is based on their individual healthcare insurance plans and duration of treatment.

Advertisement

Continue reading at Reuters »